阿列克提尼布用于治疗转移性患者.
Daniel Samacá-Samacá1, Laura Prieto-Pinto2, Andrés Yepes Peréz3
1IQVIA, Real World Insights, Bogotá, Colombia.
Lung cancer management
|June 8, 2023
概括
与crizotinib相比,alectinib在治疗ALK阳性非小细胞肺癌 (NSCLC) 中表现出更高的疗效和更好的安全性. 这项分析证实了alectinib的存在.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 无细胞淋巴瘤激酶 (ALK) 阳性非小细胞肺癌 (NSCLC) 是一个独特的亚型.
- 包括ALK抑制剂在内的向疗法已经彻底改变了治疗模式.
研究的目的:
- 为了比较alectinib与其他ALK抑制剂的疗效和安全性.
- 评估转移或局部晚期ALK阳性NSCLC患者的治疗结果.
主要方法:
- 系统性文献审查至2021年11月.
- 频率主义网络的元分析 (随机效应模型).
- 级别证据概况评估.
主要成果:
- 阿列克提尼布改善了整体存活率与克里佐替尼布相比.
- 阿莱克提尼布表现出较高的无进展生存率与克里佐替尼布和谢里替尼布相比.
- 阿莱克提尼布的疗效与第二代和第三代抑制剂相比,具有良好的安全性.
结论:
- 阿列克提尼布是ALK阳性NSCLC的有效和安全的治疗选择.
- 阿列克提尼布在较旧的ALK抑制剂上提供了显著的生存益处.
- 进一步的研究可能会探索长期结果和比较有效性.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.0K
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.8K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
213
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
213
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
